Citigroup
AQST icon

Citigroup’s Aquestive Therapeutics AQST Stock Holding History

Citigroup’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$391K Buy
93,981
+52,074
+124% +$219K ﹤0.01% 4012
2026
Q1 		$174K Sell
41,907
-9,623
-19% -$39.1K ﹤0.01% 4062
2025
Q4 		$333K Buy
51,530
+46,972
+1,031% +$293K ﹤0.01% 3766
2025
Q3 		$25.5K Sell
4,558
-26,770
-85% -$116K ﹤0.01% 4734
2025
Q2 		$104K Sell
31,328
-21,836
-41% -$62.6K ﹤0.01% 4385
2025
Q1 		$154K Sell
53,164
-5,206
-9% -$15.8K ﹤0.01% 4337
2024
Q4 		$208K Buy
58,370
+1,974
+4% +$9.1K ﹤0.01% 4390
2024
Q3 		$281K Buy
56,396
+39,865
+241% +$155K ﹤0.01% 4112
2024
Q2 		$43K Sell
16,531
-34,692
-68% -$116K ﹤0.01% 4675
2024
Q1 		$218K Sell
51,223
-30,954
-38% -$103K ﹤0.01% 3979
2023
Q4 		$166K Buy
+82,177
New +$145K ﹤0.01% 3996
2022
Q4 		– Sell
-410
Closed – – 5767
2022
Q3 		$0 Sell
410
-181
-31% -$205 ﹤0.01% 5807
2022
Q2 		$0 Sell
591
-251
-30% -$334 ﹤0.01% 6214
2022
Q1 		$2K Sell
842
-348
-29% -$1.02K ﹤0.01% 6037
2021
Q4 		$5K Buy
+1,190
New +$5.97K ﹤0.01% 5654
2021
Q3 		– Sell
-1
Closed – – 5747
2021
Q2 		$0 Sell
1
-1,314
-100% -$5.25K ﹤0.01% 6114
2021
Q1 		$7K Sell
1,315
-8,823
-87% -$46.9K ﹤0.01% 5796
2020
Q4 		$54K Buy
10,138
+8,183
+419% +$49K ﹤0.01% 5969
2020
Q3 		$9K Sell
1,955
-1,665
-46% -$10.9K ﹤0.01% 6668
2020
Q2 		$18K Buy
3,620
+46
+1% +$212 ﹤0.01% 6679
2020
Q1 		$8K Buy
3,574
+2,965
+487% +$11.3K ﹤0.01% 7111
2019
Q4 		$4K Sell
609
-49
-7% -$255 ﹤0.01% 7439
2019
Q3 		$2K Sell
658
-359
-35% -$1.34K ﹤0.01% 7519
2019
Q2 		$4K Sell
1,017
-2,645
-72% -$13.5K ﹤0.01% 7513
2019
Q1 		$25K Buy
3,662
+2,785
+318% +$19.5K ﹤0.01% 6827
2018
Q4 		$6K Sell
877
-583
-40% -$7.36K ﹤0.01% 7292
2018
Q3 		$26K Buy
+1,460
New +$24.1K ﹤0.01% 6952

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Citigroup's AQST Position: Q2 2026 in Review

Citigroup increased its Aquestive Therapeutics (AQST) stake by 124% in Q2 2026, buying an estimated $219K and bringing the position to 93,981 shares worth $391K. The position accounts for ﹤0.01% of the portfolio, ranked #4012.

Citigroup first reported a position in AQST in Q3 2018 and has held it in 27 quarters since. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Citigroup held 93,981 shares of Aquestive Therapeutics worth $391K as of Q2 2026.
  • Citigroup bought 52,074 Aquestive Therapeutics shares in Q2 2026, an estimated $219K.
  • Aquestive Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4012 holding.
  • Citigroup first reported a position in Aquestive Therapeutics in Q3 2018 and has held it in 27 quarters since.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.